Biotickr logobiotickr

Catalyst Biosciences Inc

The CBIO stock trades on Nasdaq All Markets
united states of americamicro-capgene therapyhemophiliahemophilia bhemostasis

Company Description

Catalyst Biosciences, Inc. is a research and clinical development biopharmaceutical company. The Company is focused on protease therapeutics to address unmet medical needs in disorders of the complement and coagulation systems.

Technology

One of our key competitive advantages is that our systemically dosed product candidates, due to the improvements we have made using our protease engineering platform, can be delivered subcutaneously which is less invasive, more convenient and more efficacious than intravenous IV drugs currently on the market. Our SQ product candidates demonstrate prolonged duration of activity enabling them to provide continuous therapeutic levels.

Drug Pipeline

Source: Catalyst Biosciences Inc - 20221116
Asset
Indication
Phase
CB 2679d-GT
Hemophilia B
Phase 1
 
 
 
 
 
DalcA (Dalcinonacog alfa)
Hemophilia
Phase 2
 
 
 
 
 
MarzAA (Marzeptacog alfa)
Hemophilia A
Phase 2
 
 
 
 
 

Conversation

0 following
Messages Image
Log in or sign up to join the conversation.
LoginSign up

0 Comments on CBIO stock

Newest

Trialfinder

beta

CompletedStudy of Coagulation Faction VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia

TerminatedStudy of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Hemophilia A or B

TerminatedStudy of Coagulation Factor VIIa Marzeptacog Alfa (Activated) in Subjects With Inherited Bleeding Disorders

TerminatedScreening Study to Identify Patients With Complement Factor I Deficiencies

TerminatedA Natural History Study to Assess the Clinical Outcomes of Patients With Complement Factor I Deficiency-Mediat...

Relevant Publications

beta

Outcomes and management of invasive procedures in participants with hemophilia A post gene therapy: a post hoc analysis of the GEN...

Bleed treatment with eptacog beta (rFVIIa) results in a low incidence of rebleeding in adult and adolescent patients with haemophi...

Explainability of a Deep Learning-Based Classification Model for Antineutrophil Cytoplasmic Autoantibody–Associated Glomerulonephr...

Extension Study With rVIII‐SingleChain in Previously Untreated Patients (PUPs) With Severe Haemophilia A

Trenonacog alfa safety, efficacy, and pharmacokinetics in previously treated pediatric hemophilia B